It continues to baffle me how the market can value Cannabix 4 times that of Lifeloc. A company that continues to lose over $2 million each quarter and will most likely never have a device that can quantitatively measure any type of drug.
In my opinion, Lifeloc should at least be double the value of Cannabix. The market does not see it this way. Hopefully it’s time to play some catch up.
News 
Market Data 
Discover 
AI
